Global importance: The two feline retroviruses, feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV), are global and widespread, but differ in their potential to cause disease. Viral infection -FIV: FIV, a lentivirus that shares many properties with human immunodeficiency virus (HIV), can cause an acquired immune deficiency syndrome, which predisposes cats to other infections, stomatitis, neurological disorders and tumours. Although secondary infections are common, specific opportunistic infections or acquired immunodeficiency virus-defining infections, such as those that occur with HIV, are not commonly reported in FIV-infected cats. In most naturally infected cats, FIV does not cause a severe clinical syndrome; with appropriate care, FIV-infected cats can live many years before succumbing to conditions unrelated to their FIV infection. Thus, overall survival time is not necessarily shorter than in uninfected cats, and quality of life is usually high over many years or lifelong. Viral infection -FeLV: FeLV, an oncornavirus, is more pathogenic than FIV. Historically, it was considered to account for more disease-related deaths and clinical syndromes in cats than any other infectious agent.
Classification of antiviral drugs
Most antivirals used in cats are licensed for humans and are specifically intended for treatment of human immunodeficiency virus (HiV) infection. Some of these drugs can be used to treat FiV infection because most enzymes of FiV and HiV have similar sensitivities to a range of inhibitors. Many drugs, such as nucleoside analogues, are less effective against FeLV, 4 as FeLV is not as closely related to HiV.
Antiviral compounds interfere with the viral replication cycle and can be grouped into different classes depending on the specific step at which they exert their activity. [11] [12] [13] These drug classes are summarised in Table 1 .
The most common antiretroviral drugs interfere with reverse transcription by inhibiting the retroviral enzyme reverse transcriptase (RT). Three classes of these RT inhibitors can be distinguished: nucleoside analogues (the most widely used antiviral compounds); nucleotide analogue RT inhibitors; and non-nucleoside RT inhibitors. 12 The last are usually highly selective for HIV and, thus, not useful in veterinary medicine. 14, 15 Drugs with a broader spectrum inhibit other viral enzymes, such as DNA or RNA polymerases, and thus interfere with virus genome replication or inhibit proteinases that are important for the splitting of precursor proteins during M a n a g e m e n t a n d t r e a t m e n t a p p r o a c h f o r a n F I V -i n f e c t e d c a t These recommendations are based on the expert opinion of the author (EBM grade IV -see footnote to Table 1 
Treatment of FeLV-infected cat with recurring infections < Treat recurring infections aggressively < Consider feline IFN-ω (1 x 10 6 IU SC q24h)
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These recommendations are based on the expert opinion of the author (EBM grade IV -see footnote to Table 1 Many of these analogues are also integrated into elonga ting DNA or RNA strands, but because of small differences in molecular structure, this leads to chain termination or non-functional nucleic acids. 12, 16, 17 Nucleoside analogues are accepted as false substrates not only by viral enzymes, but also by cellular enzymes, which largely accounts for their toxicity. 18
Zidovudine
Zidovudine (3'-azido-2',3'-dideoxythymidine, AZT) was first synthesised in the 1960s 19 as a potential anticancer drug. in 1985 it was shown to be effective against HiV, 20 and 2 years later it was the first drug to be approved for the treatment of HiV infection. 21 Zidovudine not only inhibits RT, but also cellular polymerases, and this leads to bone marrow suppression. Thus, regular blood cell counts are necessary during zidovudine treatment because non-regenerative anaemia is a common side effect. 22 A complete blood count should be performed weekly for the first month. If values are stable after the first 4 weeks, a monthly recheck is recommended. Cats with bone marrow suppression should not be treated with zidovudine. A study in which FIV-infected cats were treated with zidovudine for 2 years has shown that the drug is well tolerated in most cats. 23 Haematocrit can decline within 3 weeks of initiating treatment to approximately 60% of baseline levels, but recovers in most cases, even without discontinuation of treatment. If the haematocrit drops below 20%, discontinuation is recommended, and anaemia usually resolves within a few days. 23 Other side effects in cats, including vomiting or anorexia, are rare. < FIV Zidovudine inhibits FIV replication in vitro 22, [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] and in vivo; 22, 37, 38 it reduces plasma viral load, improves the immunological and clinical status of FIV-infected cats, increases quality of life, and prolongs life expectancy. 39 In placebo-controlled trials, zidovudine improved stomatitis ( Figure 2 ) and increased the CD4/CD8 ratio in naturally FIV-infected cats (EBM grade I). 22, 23, 37 Neurological abnormalities also tend to respond favourably to treatment with zidovudine. In some cats with FIVassociated neurological signs, a marked improvement occurs within the first few days of therapy. As is the case in HIV, evidence exists that FIV can become resistant to nucleoside analogues. Zidovudineresistant FIV mutants can arise after only 6 months' use, with a single point mutation in the FIV gene being responsible for the resistance. 32 < FeLV Zidovudine is effective against FeLV in vitro. [40] [41] [42] [43] [44] [45] It has also been shown to be effective in treating cats with early experimental infection. When treated less than 1 week after challenge, cats were protected from bone marrow infection and persistent viraemia (EBM grade II). 45, 46 In a study in which cats naturally infected with FeLV were treated with zidovudine for 6 weeks, however, treatment did not lead to a significant improvement in clinical, laboratory, immunological or virological parameters (EBM grade I). 47 Thus, overall therapeutic efficacy of zidovudine is less promising in FeLV-infected cats than in FIV-infected cats.
Stavudine
(2',3'-didehydro-2',3'-dideoxythymidine, d4T) is another drug with efficacy against HiV, [48] [49] [50] [51] and was approved for treatment of HiV infection in 1994. < FIV Stavudine is active against FIV in vitro. [28] [29] [30] 33, 36, 44, 52 Mutants of FIV that are resistant to stavudine and cross-resistant to several other antivirals, including zidovudine, have been detected. Resistance is caused by a single point mutation in the RT-encoding region of the pol gene. 36 No in vivo data in FIVinfected cats are available. < FeLV The activity of stavudine against FeLV has not been determined.
< A nucleoside consists of a nitrogenous base covalently attached to a sugar (ribose in RNA, 2-deoxyribose in DNA) < A nucleotide consists of a nitrogenous base, a sugar and a phosphate group A nucleic acid (RNA and DNA) contains a chain of nucleotides covalently linked together to form a sugar-phosphate backbone with protruding nitrogenous bases. Prior to integration of these nucleotides (or monophosphates) into the nucleic acid, three phosphate groups have to be bound to the nucleoside (triphosphates), two of which are removed, releasing energy during elongation of the nucleic acid chain. 12 
Figure 2 Severe stomatitis due to FIV infection. The nucleoside reverse transcriptase inhibitor, zidovudine, has a proven (EBM grade 1) effect on stomatitis in FIV-infected cats
Didanosine didanosine (2',3'-dideoxyinosine, ddi) is also used to treat HiV infection in humans. it was shown to be active against HiV in 1986, 53 and was the second drug to be approved for treatment of HiV infection. it has been marketed since 1991. 12 < FIV Didanosine is active against FIV in vitro. 25, 28, [30] [31] [32] [33] [34] 36, 54 In one experimental study, FIV replication was significantly suppressed in animals treated with didanosine, but treatment contributed to the development of antiretroviral toxic neuropathy (EBM grade II). 55 < FeLV Didanosine is also active against FeLV in vitro, 42, 44 but its in vivo efficacy is unknown.
Zalcitabine
Zalcitabine (2',3'-dideoxycytidine, ddC) was previously used to treat HiV infection in humans. 56 it was shown to be active against HiV in 1986, 53 and was approved by the US Food and drug Administration in 1992. However, it ceased being marketed in 2006. due to its toxicity, zalcitabine should not be used at concentrations over 5 mg/kg/h by continuous infusion in feline patients. 57 < FIV In vitro, antiviral efficacy has been demonstrated against FIV. [25] [26] [27] 29 ,31-33,36,54 A mutant of FIV that is resistant to zalcitabine was selected in cell culture and showed crossresistance to other antiviral compounds. 54 No in vivo data exist demonstrating efficacy in FIV-infected cats. < FeLV Zalcitabine is effective against FeLV in vitro and has been used in experimental studies to treat FeLV-infected cats. 44,57 -59 It has a very short half-life and, therefore, has been administered via either an intravenous (IV) bolus or controlled-release subcutaneous (SC) implants. 57 Controlled-release delivery of zalcitabine inhibited de novo FeLV replication and delayed the onset of viraemia after experimental infection; however, when treatment was discontinued an equivalent incidence and level of viraemia was established rapidly. 58 In a study evaluating the prophylactic antiviral activity of zalcitabine against FeLV, the drug was administered by continuous IV infusion for 28 days. Higher doses were extremely toxic, causing death in 8/10 cats. Lower doses caused thrombocytopenia. Only 1/10 cats remained FeLV antigen-negative when receiving the low dose, although the onset of viraemia was delayed for several weeks (EBM grade II). 57 Lamivudine Lamivudine (2R,cis-4-amino-l-[2-hydroxymethyl-1,3-oxathiolan-5-yl]-[1H]-pyrimidin-2one, 3TC) is also an approved anti-HiV drug. < FIV Lamivudine is active against FIV in vitro. 24, 30, 38 A combination of zidovudine and lamivudine was shown to have synergistic anti-FIV activities in cell culture. 38 FIV mutants resistant to lamivudine containing a point mutation in the RT gene were selected in vitro and showed cross-resistance to zidovudine. 32 In one in vivo study, cats experimentally infected with FIV were treated with a high dose zidovudine/lamivudine combination. 38 Treatment protected some cats when started before infection, but the zidovudine/lamivudine combination had no anti-FIV activity in chronically infected cats. Severe side effects, including fever, anorexia and marked haematological changes, were observed in some of the cats receiving the high dose dualdrug treatment (EBM II). 38 < FeLV No data on the anti-FeLV activity of lamivudine are available.
Nucleotide analogue reverse transcriptase inhibitors
Nucleotide analogue RT inhibitors interact with the catalytic site of the RT and are incorporated into the elongating proviral dNA strand, subsequently causing strand termination. 12, 15 They compete with the natural nucleotides and thus function as competitive substrate inhibitors. in these respects they are similar to nucleoside RT inhibitors. However, in contrast to nucleoside RT inhibitors, nucleotide RT inhibitors contain a phosphate group and therefore need only two intracellular phosphorylation steps to be converted into their active forms. 12 This circumvents the first (and often rate-limiting) phosphorylation step. 15, 60 Adefovir Adefovir (2-[6-amino-9H-purin-9-yl]-ethoxymethyl-phosphonic acid, PMEA) is active against herpesviruses, hepadnaviruses (hepatitis B) and retroviruses. 61 Adefovir belongs to the acyclic nucleoside phosphonates, in which the alkyl side chain of purines and pyrimidines is linked to a modified phosphate moiety and a C-P phosphonate linkage replaces the normal O5'-P phosphate linkage. 60 This phosphonate bond is nonhydrolysable, which makes it more difficult to cleave off these compounds once they have been incorporated at the 3'-terminal end of the elongating proviral DNA strand. 12 < FIV Adefovir inhibits FIV replication in vitro. 62 Several studies have investigated the efficacy of adefovir in cats either experimentally or naturally infected with FIV. 10, [63] [64] [65] [66] [67] Some of these studies have reported some efficacy, but also severe side effects, mainly in the form of non-regenerative anaemia. More recently, adefovir was used in FIV-infected cats in a 6 week placebo-controlled, double-blind clinical trial; 10 cats received the drug (10 mg/kg SC twice weekly) and 10 cats received placebo. 68 There was no decrease in proviral or viral loads in treated cats and they developed a progressive anaemia, which is a common adverse effect of nucleotide analogues (EBM grade I). 68 < FeLV Adefovir is active against FeLV in vitro. 69 In a study in experimentally infected cats, adefovir prevented the development of persistent FeLV viraemia if used early in the infection (EBM grade II); 69 but the drug was not effective in a placebo-controlled, double-blind study in naturally infected cats when used for 3 weeks (EBM grade I). 64 
Tenofovir
The antiviral spectrum of tenofovir (2R-1-[6-amino-9H-purin-9-yl]-propan-2-yl-oxymethyl-phosphonic acid, PMPA) is narrower than that of adefovir, in that it does not extend to herpesviruses, but is confined to hepadnaviruses and retroviruses. 61 Tenofovir is currently the only nucleotide RT inhibitor approved for the treatment of HiV infection; it is marketed as the prodrug tenofovir disoproxil fumarate. 60 Since it was licensed in 2001, it has become one of the most commonly used drugs in HiV therapy. 12, 17 < FIV Tenofovir is effective against FIV in vitro, 35,70 but in vivo studies have not been published to date. < FeLV Tenofovir has also been shown to be effective against FeLV in vitro. 71 However, in vivo data in FeLV-infected cats are likewise not available.
Non-nucleoside reverse transcriptase inhibitors
Most of the non-nucleoside RT inhibitors are highly specific for HiV. Unlike nucleoside and nucleotide RT inhibitors, which bind to the catalytic site of RT, non-nucleoside RT inhibitors interact with an allosteric site of the enzyme 12 and are not incorporated into the proviral dNA strand. 15 They are classified as non-competitive inhibitors of RT and do not require intracellular activation to inhibit the enzyme. 15, 16 Non-nucleoside RT inhibitors are a group of structurally diverse compounds that all bind a single site in the HIV RT enzyme. 72 The interaction with the allosteric site, which is located in close proximity to the catalytic site, leads to a number of conformational changes within the RT. 72, 73 Among other effects, these changes cause a decrease in the interaction between the DNA primer and the polymerase domain of the enzyme and, thus, interfere with virus replication. 72, 73 The classical non-nucleoside RT inhibitors are not active against FIV and FeLV; however, there is one old drug, suramin, that can be classified as a non-nucleoside RT inhibitor and has been used in veterinary medicine.
Suramin
Suramin (1-[3-benzamido-4-methylbenzamido] naphthalene-4,6,8-trisulfonic acid sym-3'urea sodium salt), a sulfated naphthylamine and trypan red derivative, is one of the oldest known antimicrobial agents. it is used as a antitrypanosomal agent as well as for the treatment of some (eg, prostatic) tumours. 74 it also has an inhibitory effect on the RT activity of retroviruses and has been used in patients with HiV infection. 75 Suramin inhibits RT by interacting with the template-primer binding site of the enzyme. It competitively binds to the primer binding site and inhibits the template-primer binding that is necessary for DNA prolongation; thus, suramin can be classified as a non-nucleoside RT inhibitor. 76 Suramin is associated with a significant number of severe side effects in humans: nausea and anaphy lactic shock as immediate reactions during administration; peripheral neuritis leading to palmar-plantar hyperaesthesia, photophobia, skin reactions, agranulocytosis, haemolytic anaemia and destruction of the adrenal cortex as later side effects. 74, 75, [77] [78] [79] Severe side effects have to be expected in cats as well.
Most of the non-nucleoside RT inhibitors are highly specific for HIV.
Only an old drug of this class, suramin, has been used in veterinary medicine.
< FIV The efficacy of suramin against FIV is unknown. < FeLV Suramin has not been investigated against FeLV in vitro, but has been used to treat FeLV-infected cats, although only a limited number of cats have been evaluated in uncontrolled studies. In one study, serum viral infectivity ceased transiently in two cats with naturally acquired FeLV infection but returned to high levels approximately 14 days after treatment was stopped (EBM grade III). 80 In another study, six anaemic FeLV-infected cats received suramin and, within 4-14 days, erythropoiesis improved. However, progenitor cells remained infected (EBM grade III). 81
Nucleotide synthesis inhibitors
Nucleotide synthesis inhibitors interfere with dNA and RNA synthesis, but not by mimicking nucleosides. They usually have a broad spectrum of activity, but also marked toxicity. Foscarnet and ribavirin have been used in veterinary medicine.
Foscarnet
Foscarnet (phosphonoformic acid, PFA) has a wide spectrum of activity against dNA and RNA viruses, including retroviruses. Foscarnet interferes with exchange of pyrophosphate from deoxynucleoside triphosphate during viral replication by binding to a site on RT or dNA polymerase. 82 This drug has only a short effect; after treatment is stopped, viral replication is reactivated. Foscarnet is mostly administered iV by continuous infusion because of its short half-life, a property that has also been demonstrated in cats. 83 oral application is possible but can cause irritation of mucous membranes and oral bleeding.
Foscarnet has many side effects in humans as well as in cats, such as nephrotoxicity and myelosuppression. It is also toxic to epithelial cells and mucous membranes, and gastrointestinal side effects and ulcerations of genital epithelium can occur. In addition, it chelates cations, such that hypocalcaemia, hypomagnesaemia and hypokalaemia can develop. 84, 85 < FIV In vitro, foscarnet has been shown to be active against FIV, but foscarnet-resistant FIV strains can develop. 25 No in vivo studies have been published in the literature. < FeLV Foscarnet is also active against FeLV in vitro, 86 but no published in vivo data exist.
Ribavirin
Ribavirin (1-[β-d-ribofuranosyl]-1H-1,2,4triazole-3-carboxamide, RTCA) has marked in vitro antiviral activity against a variety of dNA and RNA viruses. 87 Ribavirin has multiple effects on virus replication, such as allow-ing dNA synthesis to occur, but preventing triphosphate synthesis by inhibiting the enzyme inosine monophosphate dehydrogenase (essential for synthesis of nucleotides); it thus prevents nucleotide production. 87 Systemic application of ribavirin is limited because of side effects. 88 Side effects in cats in several studies (even using low doses) have included haemoly sis, which develops as a result of sequestration of the drug in erythrocytes. 89, 90 in addition, there is a dose-related toxic effect on bone marrow, primarily on megakaryocytes (resulting in thrombocytopenia and haemorrhage) and erythroid precursors (resulting in non-regenerative anaemia). With prolonged treatment or higher doses, the drug suppresses production of neutrophilic granulocytes. Liver toxicity occurs too. An attempt to decrease the toxicity of ribavirin by incorporating it into lecithin-containing liposomes and giving it at lower doses was not successful. 91 < FIV and FeLV Ribavirin is active against many viruses in vitro, including FIV and FeLV. 33, 39 No in vivo studies are published. Therapeutic concentrations are difficult to achieve because of its toxicity, and cats are extremely sensitive to the side effects. 90
Receptor homologues/ antagonists
Receptor homologues/antagonists either bind to the virus or to the cellular receptor and thereby inhibit binding of the virus to the cell surface. Most of these drugs are highly selective for HiV and not useful for veterinary medicine. An exception are the bicyclams (eg, plerixafor), which can be used in cats with FiV infection because of similarity between HiV and FiV with respect to chemokine receptor usage. 92, 93 Chemokine receptors belong to a group of seven transmembrane proteins in which signal transmission is afforded through rapid influx of calcium into the cell. They are essential co-receptors for HiV and FiV in the infection of Cd4+ lymphocytes. 94 CXCR4 is the major receptor for FiV infection, but other receptors also have been shown to mediate viral binding. 95 By binding to CXCR4, bicyclams prevent interaction of CXCR4 with other ligands, thereby inhibiting the entry of HiV or FiV into the cell. [96] [97] [98] 
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Plerixafor Plerixafor (1,1'-[1,4 -phenylenbismethylene]bis [1, 4, 8, 11 -tetraazacyclotetradecane]octachloride dehydrate, AMd3100) is the prototype compound among the bicyclams. it is not on the market as an anti-HiV drug, but is used in humans for stem cell mobilisation. 99 Plerixafor is administered to cats at a dose of 0.5 mg/kg SC q12h. Magnesium and calcium levels should be monitored regularly during treatment. 68 < FIV Plerixafor is active against FiV in vitro. 97 its efficacy was investigated in naturally FiV-infected cats in a placebocontrolled, double-blind clinical trial. 68 Treatment with plerixafor resulted in a significant decrease in provirus load; a decrease in serum magnesium levels was also recorded, although this did not have any clinical consequences. No development of resistance of FiV isolates to plerixafor was found during treatment (EBM grade i). 68 < FeLV Efficacy against FeLV has not been determined, but plerixafor is likely ineffective against this retrovirus due to the different receptors that FeLV uses for cell entry. 100
Integrase inhibitors
The enzyme integrase catalyses strand transfer (3'-end joining), which inserts both viral dNA ends into a host cell chromosome. The high degree of conservation of integraseactive sites across many retroviruses suggests that FiV and FeLV can be sensitive to integrase inhibitors. 101 The mechanism of action of these drugs is inhibition of integration of the pro viral dNA that is produced by reverse transcription of the viral RNA genome. 71
Raltegravir
Raltegravir is used in humans as an anti-HiV compound. < FIV Raltegravir is effective against FIV in vitro. 102 No in vivo studies have been published so far. < FeLV Raltegravir has recently been shown to be highly effective in vitro in several feline cell lines for inhibition of FeLV. 71, 101 The effective concentration of raltegravir had no effect on cell viability and did not induce apoptosis, suggesting that this might also be an effective and safe drug in vivo. 55 However, raltegravir is partly eliminated as glucuronide, via a metabolic pathway that is not very efficient in cats, and this increases the risk of toxicity due to drug accumulation. 99 A very recent study evaluated efficacy and safety of raltegravir in seven cats with experimentally induced progressive FeLV infection. 103 Raltegravir was administered at 40 mg PO q12h for 6.5 weeks and then at 80 mg PO q12h for 2.5 weeks. No control group was included in the study. The treatment was successful in reducing viraemia in each cat, with up to 1 log 10 reduction in viral RNA in 4/7 cats; however, viraemia rebounded in all cats after treatment was stopped. The drug reached sufficient plasma concentrations with both doses. It was found to be safe, with no harmful side effects (EBM grade III). 103 Interferons interferons (iFNs) are polypeptide molecules with a variety of biological functions. 104 They play an important role in mediating antiviral and antigrowth responses and in modulating the immune response. 105 They can be divided into two major types -type i and type ii iFNs -both of which show antiviral properties. Type i iFNs, including iFN-α, iFN-β and iFN-ω, are produced by virus-infected cells. 104,106 Type ii iFN, consisting of only iFN-γ, is produced by activated T lymphocytes and natural killer cells in response to their recognition of virus-infected cells. 107 IFNs act in an autocrine or paracrine fashion, 108 inducing an antiviral state in noninfected cells. IFNs bind to specific cell surface receptors and result in the transcription of IFN-stimulated genes. The products of these genes are proteins with potent antiviral properties which interfere with various stages of viral replication. 108 Several studies suggest that retroviral protein synthesis is not affected by IFNs and conclude that the antiviral activity of IFNs is related to interference with later stages of the viral replication cycle, such as virion assembly and release. 104,109 Interferons also trigger virus-infected cells to undergo apoptosis by activating the expression of genes that contribute to the process of programmed cell death. 107, 109 Thereby IFNs prevent the spread of virus from infected cells and aid in the clearance of virus infection. 107 Human IFNs have been manufactured by recombinant DNA technology and are available commercially. Recombinant feline IFN-ω is on the market in Japan, Australia and European countries, licensed for use in cats and dogs.
The integrase inhibitor raltegravir has been used safely in cats, but further work is required to determine its potential as an anti-retroviral drug.
Human interferon-α
Recombinant human interferon-α (iFN-α) has antiviral and immunomodulatory activity, and is active against many dNA and RNA viruses. 108 There are two common treatment regimens for use of iFN-α in cats: SC injection of high doses (1 x 10 4 to 1 x 10 6 iU/kg q24h) or oral application of low doses (1-50 iU/kg q24h). When given parenterally to cats, human iFN-α becomes ineffective after 3-7 weeks due to the development of neutralising antibodies that limit its activity. 46 IFN-α can be given orally for a longer period as no antibodies will develop during oral treatment, and it has been used in this manner to treat FIV and FeLV infections. However, given orally, IFN-α is inactivated by gastric acid and destroyed by trypsin and other proteolytic enzymes in the duodenum. 110 Thus, direct antiviral effects are unlikely after oral application, but it still seems to have immunomodulatory activity. After oral application, IFN-α can bind to mucosal receptors in the oral cavity, stimulating the local lymphoid tissue. This leads to cytokine release on lymphatic cells in the oral or pharyngeal area, triggering a cascade of immunological responses that finally act systemically. [111] [112] [113] < FIV IFN-α is active against FIV in vitro. 114 Although frequently used in the field for treating FIV-infected cats, no controlled studies have evaluated the effect of high dose parenteral IFN-α in FIV-infected cats.
Use of low dose oral IFN-α in sick cats naturally infected with FIV (50 IU/kg on the oral mucosa q24h for 7 days on alternating weeks for 6 months, followed by a 2 month break, and then repetition of the 6 month treatment) resulted in improvement of clinical signs in a placebo-controlled, double-blind study. 115 < FeLV Several studies have been conducted on the use of IFN-α in FeLV-infected cats. In vitro, FeLV replication is inhibited by IFN-α. 116 One study evaluated the therapeutic efficacy of high dose IFN-α (1.6 x 10 4 to 1.6 x 10 6 IU/kg SC q24h) in experimentally FeLV-infected cats with persistently high levels of antigenaemia. 46 Treatment resulted in a significant decrease in circulating FeLV antigen beginning 2 weeks after the initiation of therapy (EBM grade II). 46 However, because of anti-IFN-α antibody development, cats became refractory to therapy 3 or 7 weeks after starting treatment. 46 In a placebo-controlled, doubleblind study in naturally FeLV-infected cats using a similar high dose regimen, treatment with IFN-α (1 x 10 5 IU/kg SC q24h for 6 weeks) did not lead to a significant improvement in clinical, laboratory, immuno logical or virological parameters (EBM grade I). 47 Low dose oral IFN-α was used in a placebocontrolled study in experimentally induced FeLV infection; 0.5 IU/cat (eight cats) or 5 IU/cat (five cats) was given (following experimental challenge) on 7 consecutive days on alternate weeks for a period of 1 month. 111 No difference was found in the development of viraemia between groups; however, treated cats had significantly fewer clinical signs and longer survival times when compared with the placebo group (with a better response in the cats given 0.5 IU/cat) (EBM grade II). 111 Several uncontrolled field studies have also reported a beneficial response in cats when treated with low dose oral IFN-α, 116, 117 but they only included a limited number of cats and the findings are impossible to interpret without control groups (EBM grade III). In a larger study, the outcome of 69 FeLV-infected cats with clinical signs that were treated with low dose oral IFN-α (30 IU/kg for 7 consecutive days on a 1 week on/1 week off schedule) was compared with historical controls; significantly longer survival times were reported in the treated cats (EBM grade III). 117 In a placebo-controlled study, treatment of sick client-owned FeLV-infected cats with low dose oral IFN-α (30 IU/cat for 7 consecutive days on a 1 week on/1 week off schedule) did not result in a significant difference in FeLV status, survival time, clinical or haematological parameters, or owners' subjective impression when compared with a placebo group. Thus, this controlled study was not able to demonstrate efficacy (EBM grade I). 118
Feline interferon-ω
Feline interferon-ω (iFN-ω), the corresponding feline interferon, is licensed as a veterinary medicine in Japan, Australia and European countries. Feline iFN-ω is a recombinant product that is produced by baculoviruses containing the feline sequence for this iFN that replicate in silkworms after infection. Results of studies investigating the efficacy of feline iFN-ω against FiV and FeLV are summarised in the box on page 935.
Future priorities
Unfortunately, the level of efficacy of antiviral chemotherapy is often poor and the duration of treatments used in clinical trials is often inappropriate for infections with such long clinical courses. Additionally, the degree of generalisability between experimental infections in cats kept under laboratory conditions and pet cats infected with field strains is unknown. Therefore, it is very important that more well-designed double-blind, placebocontrolled trials using antivirals in naturally retrovirus-infected cats are undertaken to allow judgement on treatment efficacy and side effects of different antiviral compounds. E f f i c a c y o f v e t e r i n a r y l i c e n s e d f e l i n e i n t e r f e r o n -ω FIV IFN-ω inhibits FIV replication in vitro. 114 One placebo-controlled, multi-centre study investigated the efficacy of feline IFN-ω against FIV infection in 62 naturally infected cats treated with high dose IFN-ω (1 x 10 6 IU/kg SC q24h) on 5 consecutive days. This study did not find significant changes in survival rate in treated cats compared with a placebo group, although some clinical improvement was noted (EBM grade I). 119 In another study evaluating naturally FIV-infected cats housed in a shelter, some clinical improvement was seen with IFN-ω treatment administered at the above-mentioned high dose, but in this study there was no placebo control. 106 Haematological values remained within reference intervals, and there were no biochemical abnormalities asso ciated with IFN-ω treatment (EBM grade III). 106 A recent study evaluated use of an orally administered medium-high dose of IFN-ω for the treatment of symptomatic, client-owned, naturally FIV-infected cats. 120 The treatment protocol was 1 x 10 5 IU/cat PO q24h for 90 consecutive days, administered by the cats' owners. A historical group treated subcutaneously with the high dose licensed protocol (1 x 10 6 IU/kg SC q24h) was used as a control for comparison, but no placebo group was included. Treatment resulted in significant improvement of clinical scores post-treatment, compared with pre-treatment values. Furthermore, there was no significant difference between the SC high dose historical control group and the PO medium-high dose group, suggesting that oral administration of IFN-ω in a lower dose could be used as an alternative to the licensed protocol at reduced cost (EBM grade III). 120 In a recently published study that assessed viraemia, provirus load and blood cytokine profile in naturally FIV-infected cats treated either with oral or subcutaneous feline IFN-ω (in the same dosages described above), but again without placebo control, there was no change in viraemia or in most of the cytokine levels measured (EBM grade III), 121 which questions the efficacy noted in previous clinical trials without placebo control. The fact that virus load remained unchanged in the cats, but some clinical improvement could be observed, invites the conclusion that IFN-ω might have an effect on secondary infections rather than on FIV itself. 104 In summary, studies to date on feline IFN-ω in FIV-infected cats have reported differing outcomes, and definitive conclusions cannot be drawn without additional studies incorporating sufficiently high numbers of naturally infected cats that are randomised, placebo-controlled and double-blinded.
Interferons
FeLV
Feline IFN-ω inhibits FeLV replication in vitro. 122 In a placebocontrolled field study, 48 cats with FeLV infection were treated with high dose IFN-ω at 1 x 10 6 IU/kg q24h SC on 5 consecutive days. This treatment was applied three times, with several treatment-free weeks in-between. There was a significant difference recorded in the survival time of treated vs untreated cats in a 9 month follow-up period (EBM grade I). 119 No virological parameters, however, were measured throughout the study. This supports the hypothesis that the IFN-ω was inhibiting secondary infections rather than having a direct anti-FeLV effect. In another study evaluating FeLV-infected cats housed in a shelter, some clinical improvement was noted with IFN-ω treatment using the same dose as described above, but no placebo group was included, precluding a definitive assessment (EBM grade III). 106 No studies have been published so far on the oral use of IFN-ω in FeLV-infected cats.
In FIV and FeLV infection, a treatment protocol of 1 x 10 6 IU/kg SC q24h on 5 consecutive days is suggested. No major severe side effects have been reported in cats. 120 
